Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells

Human Molecular Genetics

Volumn 21, Issue 21, 2012, Pages 4615-4627

  Giessrigl, Benedikt ^a,b   Krieger, Sigurd ^a   Rosner, Margit ^a   Huttary, Nicole ^a   Saiko, Philipp ^a   Alami, Mouad ^c   Messaoudi, Samir ^c   Peyrat, Jean François ^c   Maciuk, Alexandre ^c   Gollinger, Michaela ^a   Kopf, Sabine ^a   Kazlauskas, Egidijus ^d   Mazal, Peter ^a   Szekeres, Thomas ^a   Hengstschläger, Markus ^a   Matulis, Daumantas ^d   Jäger, Walter ^b   Krupitza, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITÉ PARIS SUD   (France)

^d VILNIUS UNIVERSITY   (Lithuania)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; FULVESTRANT; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; PROTEIN TYROSINE PHOSPHATASE; TAMOXIFEN;

ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE PARAMETERS; CELL PROLIFERATION; CONTROLLED STUDY; DATA ANALYSIS; ENZYME DEGRADATION; FEMALE; HUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BENZOQUINONES; CDC25 PHOSPHATASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NOVOBIOCIN; PANCREATIC NEOPLASMS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS;

EID: 84867803881     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds303     Document Type: Article

References (36)

1. Mihaljevic, A.L., Michalski, C.W., Firess, H. and Kleeff, J. (2010) Molecular mechanisms of pancreatic cancer-understanding proliferation, invasion and metastasis. Langenbecks Arch. Surg., 395, 295-308.
2. Fahrig, R., Quietzsch, D., Heinrich, J.C., Heinemann, V., Boeck, S., Schmid, R.M., Praha, C., Liebert, A., Sonntag, D., Krupitza, G. et al. (2006) RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients. Anticancer Drugs, 17, 1045-1056.
3. Heinrich, J.C., Tuukkanen, A., Schroeder, M., Fahrig, T. and Fahrig, R. (2011) RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J. Cancer Res. Clin. Oncol., 137, 1349-1361.
4. Evans, D.B., Abbruzzese, J.L. and Willett, C.G. (2001) Cancer of the pancreas. In: DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds), Cancer: Principles and Practice of Oncology. Lipincott, Philadelphia, pp. 1126-1161.
5. Niederhuber, J.E., Brennan, M.F. and Menck, H.R. (1995) The national cancer data base report on pancreatic cancer. Cancer, 76, 1671-1677.
6. Huguet, F., Girard, N., Guerche, C.S., Hennequin, C., Mornex, F. and Azria, D. (2009) Chemoradiotherapy in the management of locally advanced pyncreatic carcinoma: a qualitative systematic review. J. Clin. Oncol., 27, 2269-2277.
7. Khalil, A.A., Kabapy, N.F., Deraz, S.F. and Smith, C. (2011) Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim. Biophys. Acta., 1816, 89-104.
8. Cotto, J.J. and Morimoto, R.I. (1999) Stress induced activation of the heat shock response: cell and molecular biology of heat shock factors. Biochem. Soc. Symp., 64, 105-118.
9. Lindquest, S. and Craig, E.A. (1998) The heat-shock proteins. Annu. Rev. Genet., 22, 631-677.
10. Madlener, S., Rosner, M., Krieger, S., Giessrigl, B., Gridling, M., Vo, T.P., Leisser, C., Lackner, A., Raab, I., Grusch, M. et al. (2009) Short 428C heat shock induces phosphorylation and degradation of Cdc25A which depends on p38MAPK, Chk2 and 14.3.3. Hum. Mol. Genet., 18, 1990-2000.
11. Nilsson, I. and Hoffmann, I. (2000) Cell cycle regulation by the Cdc25 phosphatase family. Prog. Cell Cycle Res., 4, 107-114.
12. García-Morales, P., Carrasco-García, E., Ruiz-Rico, P., Martínez-Mira, R., Menéndez-Gutiérrez, M.P., Ferragut, J.A., Saceda, M. and Martínez-Lacaci, I. (2007) Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines. Oncogene, 26, 7185-7193.
13. Tse, A.N., Sheikh, T.N., Alan, H., Chou, T.C. and Schwartz, G.K. (2009) 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumour cells by depleting Chk1 and Wee1. Mol. Pharmacol., 75, 124-133.
14. Park, S.J., Kostic, M. and Dyson, H.J. (2011) Dynamic interaction of Hsp90 with its client protein p53. J. Mol. Biol., 411, 158-173.
15. Chen, M.S., Ryan, C.E. and Piwnica-Worms, H. (2003) Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol. Cell. Biol., 23, 7488-7497.
16. Marcu, M.G., Chadli, A., Bouhouche, I., Catelli, M. and Neckers, L.M. (2000) The heat shock protein 90 antangonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem., 275, 37181-37186.
17. Le Bras, G., Radanyi, C., Peyrat, J.F., Brion, J.D., Alami, M., Marsaud, V., Stella, B. and Renoir, J.M. (2007) New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J. Med. Chem., 50, 6189-6200.
18. Radanyi, C., Le Bras, G., Marsaud, V., Peyrat, J.F., Messaoudi, S., Catelli, M.G., Brion, J.D., Alami, M. and Renoir, J.M. (2009) Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett., 274, 88-94.
19. Radanyi, C., Le Bras, G., Bouclier, C., Messaoudi, S., Peyrat, J.F., Brion, J.D., Alami, M., Renoir, J.M. and Radanyi, C. (2009) Tosylcyclonivobiocic acids promote cleavage of the Hsp90-associated cochaperone p23. Biochem. Biophys. Res. Comm., 379, 514-518.
20. Mollappour, M., Tsutsumi, S., Donelly, A.C., Beebe, K., Tokita, M.J., Lee, M.J., Lee, S., Morra, G., Bouboulia, D., Scroggins, B.T. et al. (2010) Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol. Cell., 37, 333-343.
21. Miyasaka, Y., Nagai, E., Yamaguchi, H., Fujii, K., Inoue, T., Ohuchida, K., Yamada, T., Mizumoto, K., Tanaka, M. and Tsuneyoshi, M. (2007) The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. Clin. Cancer Res., 13, 4371-4377.
22. Skitzki, J.J., Repasky, E.A. and Evans, S.S. (2009) Hyperthermia as an immunotherapy strategy for cancer. Curr. Opin. Investig. Drugs, 10, 550-558.
23. Dewhirst, M.W., Vujaskovic, Z., Jones, E. and Thrall, D. (2005) Re-setting the biologic rationale for thermal therapy. Int. J. Hyperthermia., 21, 779-790.
24. Kraybill, W.G., Olenki, T., Evans, S.S., Ostberg, J.R., O'Leary, K.A., Gibbs, J.F. and Repasky, E.A. (2002) A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models. Int. J. Hyperthermia, 18, 253-266.
25. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E. and Thun, M.J. (2003) Cancer statistics, 2003. C. A. Cancer J. Clin., 53, 5-26.
26. Bayraktar, S., Bayraktar, U.D. and Rocha-Lima, C.M. (2010) Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J. Gastroenterol., 16, 673-682.
27. Uwagawa, T., Chiao, P.J., Gocho, T., Hirohara, S., Misawa, T. and Yanaga, K. (2009) Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res., 29, 3173-3178.
28. Fujiwara, Y., Furukawa, K., Haruki, K., Shimada, Y., Iida, T., Shiba, H., Uwagawa, T., Ohashi, T. and Yanaga, K. (2011) Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition. J. Hepatobiliary Pancreat. Sci., 18, 731-739.
29. Okamoto, A., Demetrick, D.J., Spillare, E.A., Hagiwara, K., Hussain, S.P., Bennett, W.P., Forrester, K., Gerwin, B., Serrano, M., Beach, D.H. and Harris, C.C. (1994) Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA., 91, 11045-11049.
30. Chen, Y.W., Liu, J.Y., Lin, S.T., Li, J.M., Huang, S.H., Chen, J.Y., Wu, J.Y., Kuo, C.C., Wu, C.L., Lu, Y.C. et al. (2011) Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells. Mol. Biosyst., 7, 3065-3074.
31. Park, Y.J., Wen, J., Bang, S., Park, S.W. and Song, S.Y. (2006) (6)-Gingerol induces cell cycle arrest and cell death of mutant p53-expressing pancreatic cancer cells. Yonsei. Med. J., 47, 688-697.
32. Goloudina, A., Yamaguchi, H., Chervyakova, D.B., Appella, E., Fornace, A.J. Jr. and Bulavin, D.V. (2003) Regulation of human Cdc25A stability by serine 75 phosphorylation is not suficient to activate a S-phase checkpoint. Cell Cycle, 2, 473-478.
33. Busino, L., Donzelli, M., Chiesa, M., Guardavaccaro, D., Ganoth, D., Dorrello, N.V., Hershko, A., Pagano, M. and Draetta, G.F. (2003) Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature, 426, 87-91.
34. Busino, L., Chiesa, M., Draetta, G.F. and Donzelli, M. (2004) Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene, 23, 2050-2056.
35. Smith, J., Tho, L.M., Xu, N. and Gillespie, D.A. (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res., 108, 73-112.
36. Kazlauskas, E., Petrikaitė, V., Michailovienė, V., Revuckienė, J., Matulienė, J., Grinius, L. and Matulis, D. (2012) Thermodynamics of aryl-dihydroxyphenyl-thiadiazole binding to human Hsp90. PLoS ONE, 7, e36899.